403 related articles for article (PubMed ID: 34442415)
1. The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application.
Wu J
J Pers Med; 2021 Aug; 11(8):. PubMed ID: 34442415
[TBL] [Abstract][Full Text] [Related]
2. Selective Enhancing Blood Flow in Solid Tumor Tissue Is the Key for Achieving Satisfactory Delivery and Therapeutic Outcome of Nanodrugs via the EPR Effect.
Wu J
J Pers Med; 2022 Nov; 12(11):. PubMed ID: 36579542
[TBL] [Abstract][Full Text] [Related]
3. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
Maeda H; Bharate GY; Daruwalla J
Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
[TBL] [Abstract][Full Text] [Related]
4. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
Greish K
J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
[TBL] [Abstract][Full Text] [Related]
5. Human solid tumors and clinical relevance of the enhanced permeation and retention effect: a 'golden gate' for nanomedicine in preclinical studies?
Gawali P; Saraswat A; Bhide S; Gupta S; Patel K
Nanomedicine (Lond); 2023 Jan; 18(2):169-190. PubMed ID: 37042320
[TBL] [Abstract][Full Text] [Related]
6. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS.
Fang J; Sawa T; Maeda H
Adv Exp Med Biol; 2003; 519():29-49. PubMed ID: 12675206
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of EPR Effect and Efficacy of Anticancer Nanomedicine by Carbon Monoxide Generating Agents.
Fang J; Islam R; Islam W; Yin H; Subr V; Etrych T; Ulbrich K; Maeda H
Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31315251
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy--Problems, Solutions, and Prospects.
Maeda H; Tsukigawa K; Fang J
Microcirculation; 2016 Apr; 23(3):173-82. PubMed ID: 26237291
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Permeability and Retention Effect as a Ubiquitous and Epoch-Making Phenomenon for the Selective Drug Targeting of Solid Tumors.
Islam W; Niidome T; Sawa T
J Pers Med; 2022 Nov; 12(12):. PubMed ID: 36556185
[TBL] [Abstract][Full Text] [Related]
10. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.
Maeda H
Adv Drug Deliv Rev; 2015 Aug; 91():3-6. PubMed ID: 25579058
[TBL] [Abstract][Full Text] [Related]
11. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.
Nakamura H; Fang J; Maeda H
Expert Opin Drug Deliv; 2015 Jan; 12(1):53-64. PubMed ID: 25425260
[TBL] [Abstract][Full Text] [Related]
12. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
Sun D; Zhou S; Gao W
ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
[TBL] [Abstract][Full Text] [Related]
13. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
Maeda H; Wu J; Sawa T; Matsumura Y; Hori K
J Control Release; 2000 Mar; 65(1-2):271-84. PubMed ID: 10699287
[TBL] [Abstract][Full Text] [Related]
14. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.
Greish K
Methods Mol Biol; 2010; 624():25-37. PubMed ID: 20217587
[TBL] [Abstract][Full Text] [Related]
15. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting.
Maeda H
Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(3):53-71. PubMed ID: 22450535
[TBL] [Abstract][Full Text] [Related]
16. The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives.
Sun R; Xiang J; Zhou Q; Piao Y; Tang J; Shao S; Zhou Z; Bae YH; Shen Y
Adv Drug Deliv Rev; 2022 Dec; 191():114614. PubMed ID: 36347432
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines.
Islam W; Fang J; Imamura T; Etrych T; Subr V; Ulbrich K; Maeda H
Mol Cancer Ther; 2018 Dec; 17(12):2643-2653. PubMed ID: 30232144
[TBL] [Abstract][Full Text] [Related]
18. S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes.
Kinoshita R; Ishima Y; Ikeda M; Kragh-Hansen U; Fang J; Nakamura H; Chuang VT; Tanaka R; Maeda H; Kodama A; Watanabe H; Maeda H; Otagiri M; Maruyama T
J Control Release; 2015 Nov; 217():1-9. PubMed ID: 26302904
[TBL] [Abstract][Full Text] [Related]
19. Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis.
Subhan MA; Parveen F; Filipczak N; Yalamarty SSK; Torchilin VP
J Pers Med; 2023 Feb; 13(3):. PubMed ID: 36983571
[TBL] [Abstract][Full Text] [Related]
20. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.
Fang J; Nakamura H; Maeda H
Adv Drug Deliv Rev; 2011 Mar; 63(3):136-51. PubMed ID: 20441782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
